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A B S T R A C T
Diabetic kidney disease (DKD) represents an enormous burden in patients with type 2 diabetes mellitus
(T2DM). Preclinical studies using most glucose-lowering agents have suggested renal-protective effects,
but the proposed mechanisms of renoprotection have yet to be deﬁned, and the promising results from
experimental studies remain to be translated into human clinical ﬁndings to improve the prognosis of
patients at risk of DKD. Also, it is important to distinguish effects on surrogate endpoints, such as
decreases in albuminuria and estimated glomerular ﬁltration rate (eGFR), and hard clinical endpoints,
such as progression to end-stage renal disease (ESRD) and death from renal causes. Data regarding
insulin therapy are surprisingly scarce, and it is nearly impossible to separate the effects of better glucose
control from those of insulin per se, whereas favourable preclinical data with metformin,
thiazolidinediones and dipeptidyl peptidase (DPP)-4 inhibitors are plentiful, and positive effects have
been observed in clinical studies, at least for surrogate endpoints. The most favourable renal results have
been reported with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose
cotransporter type-2 inhibitors (SGLT2is). Signiﬁcant reductions in both albuminuria and eGFR
decline have been reported with these classes of glucose-lowering medications compared with placebo
and other glucose-lowering agents. Moreover, in large prospective cardiovascular outcome trials using
composite renal outcomes as secondary endpoints, both GLP-1RAs and SGLT2is added to standard care
reduced renal outcomes combining persistent macro-albuminuria, doubling of serum creatinine,
progression to ESRD and kidney-related death; however, to date, only SGLT2is have been clearly shown
to reduce such hard clinical outcomes. Yet, as the renoprotective effects of SGLT2is and GLP-1RAs appear
to be independent of glucose-lowering activity, the underlying mechanisms are still a matter of debate.
For this reason, further studies with renal outcomes as primary endpoints are now awaited in T2DM
patients at high risk of DKD, including trials evaluating the potential add-on beneﬁts of combined GLP-
1RA–SGLT2i therapies.




In parallel with the type 2 diabetes mellitus (T2DM) worldwide
pandemic, diabetic kidney disease (DKD), which is also associated
with cardiovascular (CV) morbidity and mortality, has now
become the leading cause of end-stage renal disease (ESRD)
[1]. Renal impairment in T2DM results in high healthcare
utilization and costs [2]. Thus, both the prevention of DKD and* Corresponding author at: Department of Medicine, CHU de Sart Tilman (B35),
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represent major challenges in patients with T2DM [3–5].
In addition to inhibition of the renin–angiotensin–aldosterone
system (RAAS), tight glucose control is also an established
modality for preventing the development and progression of
albuminuria [6]. Evidence suggests it can ameliorate estimated
glomerular ﬁltration rate (eGFR) declines, although these beneﬁts
appear to be most pronounced when applied to T2DM patients
with early stages of DKD and longer follow-up durations [7,8]. Most
antihyperglycaemic medications can be safely used in patients
with mild-to-moderate DKD. However, several glucose-lowering
agents are either not advisable or require dose adjustments
in cases of more advanced stages of renal disease [6–10]. Of
note, metformin, the ﬁrst-line treatment for pharmacologicalg agents on surrogate endpoints and hard clinical renal outcomes
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moderate renal dysfunction, according to recent guidelines [11].
Intensive glucose control with the classic glucose-lowering
agents, including insulin, reduces the risk of (micro)albuminuria,
although evidence is lacking that it can reduce the risk of hard
clinical renal outcomes like doubling of serum creatinine levels,
ESRD and death due to renal disease, presumably because of too-
short follow-ups in most of the available trials [12]. However, as
add-ons to standard care, new glucose-lowering agents have
demonstrated renoprotective effects beyond just improvement of
glucose control [13–16]. In particular, glucagon-like peptide-1
receptor agonists (GLP-1RAs) [17] and, even more impressively,
sodium–glucose cotransporter type-2 inhibitors (SGLT2is) [18–21]
have shown positive effects on composite renal outcomes,
including hard clinical endpoints, in T2DM patients with
established CV disease.
The aim of the present narrative review is to analyze and
compare the effects of old and new glucose-lowering agents on
surrogate renal endpoints and clinical renal outcomes in patients
with T2DM (Table 1). The underlying mechanisms responsible for
nephroprotection were mainly investigated in in-vitro and in-vivo
experiments using animal models, and are here brieﬂy discussed
for each pharmacological class.
Metformin
Metformin elicits at least part of its therapeutic activity via
activation of the AMP-activated kinase (AMPK) pathway. AMPK is a
metabolic sensor that regulates cellular energy balance, transport,
growth, inﬂammation and survival functions; in the kidney, AMPK
plays a unique role at the crossroads of energy metabolism, ion and
water transport, inﬂammation and stress [22]. Pharmacological
activators of AMPK like metformin have shown renal-protective
effects in numerous experimental studies [23]. Renal cells under
hyperglycaemic or proteinuric conditions exhibit inactivation of
cell defence mechanisms (AMPK and autophagy) and activation of
pathological pathways [mammalian target of rapamycin (mTOR),
epithelial-to-mesenchymal transition, endoplasmic reticulum
stress, oxidative stress] [24]. Activation of AMPK by metformin
suppresses endoplasmic reticulum stress by angiotensin II,
aldosterone and high glucose levels, and also reduces renal ﬁbrosis
related to transforming growth factor (TGF)-b [25]. In a
concentration-dependent manner, metformin has also exhibited
antiapoptotic effects on human podocytes via activation of AMPK
and inhibition of mTOR signalling [26]. Experimental studies in
mice concluded that the underlying mechanisms for the protective
effects of metformin against renal ﬁbrosis include AMPKa2-
dependent targeting of TGF-b1 production and AMPKa2-inde-
pendent targeting of TGF-b1 downstream signalling [27]. OtherTable 1
Effects of glucose-lowering agents on renal surrogate endpoints and clinical outcomes 
Medications Preclinical results Clinical results
In-vitro and in-vivo data Reduction of a
Metformin Positive Not proven 
Sulphonylureas None Noa
Glinides None No data 
Alpha-glucosidase inhibitors Rare No data 
Thiazolidinediones Positive Yes 
DPP-4 inhibitors Positive Yes 
GLP-1 receptor agonists Positive Yes 
SGLT2 inhibitors Positive Yes 
Insulin therapy Rare Not provenb
eGFR: estimated glomerular ﬁltration rate; ESRD: end-stage renal disease; DPP-4: d
cotransporter type 2.
a Less favourable results compared with metformin in observational studies.
b Impossible to discriminate from possible effects due to better glucose control.
Please cite this article in press as: Scheen AJ. Effects of glucose-lowerin
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carboxylase (ACC) after renal injury contributes to the develop-
ment of tubulointerstitial ﬁbrosis, and that phosphorylation of
ACC, a target for energy-sensing AMPK, is required for antiﬁbrotic
metformin actions in the kidney [28]. Thus, numerous in-vitro and
in-vivo studies have revealed nephroprotective effects with
metformin, and these effects have been demonstrated to be
mediated via the AMPK–mTOR signalling axis [29].
Metformin activates not only AMPK, but also protein deace-
tylase SIRT1. In fact, metformin has been shown to prevent the
hyperglycaemia-induced reduction of SIRT1 protein levels while
ameliorating glucose uptake into podocytes and decreasing
glomerular ﬁltration barrier permeability. Indeed, the potentiating
effect of metformin on high-glucose-induced insulin-resistant
podocytes seems to be dependent on SIRT1 activity in addition to
AMPK, thereby arguing in favour of pleiotropic effects with
metformin action [30]. Recent experimental data in a rat model of
chronic kidney disease (CKD) showed that kidneys from the
metformin group exhibited signiﬁcantly less cellular inﬁltration,
ﬁbrosis and inﬂammation, and that metformin protected against
the development of severe renal failure (while preserving calcium
phosphorus homoeostasis) and vascular calciﬁcation. Of note,
these positive effects were independent of any glucose-lowering
effect in this model using non-diabetic rats [31]. Overall, these
preclinical data suggest that the potential beneﬁts of metformin on
renal outcomes in patients with T2DM may well extend beyond its
antihyperglycaemic activity.
Nevertheless, such positive preclinical results are still awaiting
further clinical translation [32]. Indeed, human data are still rather
scarce. In the United Kingdom Prospective Diabetes Study
(UKPDS), the proportion of T2DM patients with urinary albu-
min > 50 mg/L (the only surrogate marker used as a renal
outcome in this landmark study) did not differ signiﬁcantly
between the metformin group (23%), the conventional diet-treated
group (23%) and the intensive (sulphonylurea or insulin) group
(24%) over a median follow-up of 10.7 years [33]. In A Diabetes
Outcome Progression Trial (ADOPT), a 5-year study comparing
initial therapy with metformin vs glyburide (glibenclamide) and
rosiglitazone in T2DM patients, the urinary albumin/creatinine
ratio (UACR) rose slowly in the metformin group, whereas it
initially fell with rosiglitazone and glyburide over the ﬁrst 2 years,
then rose slowly over time. On the other hand, the late decline in
eGFR with metformin was more pronounced than with rosi-
glitazone, but less marked than with glyburide [34].
Most clinical studies have been interested in the safety issues of
metformin in T2DM patients with renal impairment as regards risk
of lactic acidosis rather than the impact of metformin on surrogate
or clinical renal outcomes (for reviews, see Crowley et al. and
Inzucchi et al. [35,36]). Nevertheless, based on the relevant clinicalin preclinical animal models and clinical studies in patients with type 2 diabetes.
lbuminuria Slowing of eGFR reduction Less progression to ESRD
Not proven Not proven
Noa Noa
No data No data
No data No data
Not proven Not proven
Not proven Not proven
Yes Not proven
Yes Yes
Not provenb Not provenb
ipeptidyl peptidase 4; GLP-1: glucagon-like peptide 1; SGLT2: sodium–glucose
g agents on surrogate endpoints and hard clinical renal outcomes
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treatment of progressive renal damage [37]. Several observational
ﬁndings demonstrated better renal outcomes in T2DM patients
initiated or treated with metformin than in those initiated or
treated with sulphonylureas (see below). However, because of the
possible biases inherent in observational studies, randomized
controlled trials (RCTs) are the essential next step to conﬁrm these
ﬁndings.
Sulphonylureas
In contrast to the huge amount of experimental animal data
supporting the renal-protective effects of metformin [37], no such
data are available in the literature for sulphonylureas [38,39].
In the above-mentioned ADOPT study comparing initial therapy
with the sulphonylurea glyburide vs. metformin and rosiglitazone
in newly diagnosed T2DM patients, a late decline in eGFR was
observed in all three groups, albeit more marked with glyburide
than with either metformin or rosiglitazone over the 5-year
follow-up [34]. The Action in Diabetes and Vascular disease:
Preterax and Diamicron MR Controlled Evaluation (ADVANCE)
reported that intensive glucose control using modiﬁed-release
(MR) gliclazide prevented ESRD in patients with T2DM [40]: after a
median duration of 5 years, intensive glucose control signiﬁcantly
reduced microalbuminuria by 9%, macroalbuminuria by 30% and
risk of ESRD by 65% [hazard ratio (HR): 0.35, P = 0.02], although
there were very few such events (only 7 vs. 20 ESRD cases).
However, this effect on ESRD was conﬁrmed in the subsequent
ADVANCE-ON trial after a median of 5.4 additional years (29 vs.
53 events; HR: 0.54, P < 0.01), and the beneﬁt was greater in
patients with earlier-stage DKD and with well-controlled blood
pressure [41]. Of note, the experimental design of the study did not
allow separation of the effects of sulphonylurea per se from that of
better glucose control.
Using electronic health records from two primary-care
networks and compared with metformin as the reference,
sulphonylurea exposure in newly diagnosed T2DM patients
trended towards an association with an increased risk of
developing proteinuria [adjusted hazard ratio (aHR): 1.27, 95%
conﬁdence interval (CI): 0.93–1.74], but showed a clear association
with an increased risk of eGFR reduction to < 60 mL/min/1.73 m2
(aHR: 1.41, 95% CI: 1.05–1.91) [42].
Several retrospective comparisons were performed using the
US Veterans Affairs national database. In a cohort of 93,577 T2DM
patients who had ﬁlled an incident oral antidiabetic drug
prescription and had an eGFR  60 mL/min/1.73 m2 at inclusion,
sulphonylurea users compared with metformin users had an
increased risk of the primary outcome (persistent decline of  25%
in eGFR from baseline or a diagnosis of ESRD: aHR: 1.22, 95% CI:
1.03–1.44) [43]. These results were conﬁrmed in 13,238 veteran
T2DM patients who initiated either sulphonylurea or metformin
treatment. A higher risk of kidney function decline or death was
seen with sulphonylurea compared with metformin, and the
difference appeared to be independent of changes in glycated
haemoglobin (HbA1c), systolic blood pressure and body mass index
(BMI) over time [44]. Of 175,296 patients with newly diagnosed
T2DM and DKD, initiation of a sulphonylurea vs. metformin was
associated with a substantial increase in mortality across all ranges
of eGFR evaluated (HR ranged from 1.25 to 1.69). The biggest
absolute risk increase was observed in those with moderate-to-
severe decreases in eGFR (30–44 mL/min/1.73 m2) [45].
In a real-world cohort of T2DM patients with albuminuria
(urinary albumin creatinine ratio [UACR] > 30 mg/g) who initiat-
ed either sulphonylurea or sitagliptin as add-on dual therapy to
metformin (data extracted from the computerized medical recordsPlease cite this article in press as: Scheen AJ. Effects of glucose-lowerin
in patients with type 2 diabetes. Diabetes Metab (2018), https://doiof a large managed-care organization in Israel), while both
pharmacological approaches reduced albuminuria, sulphonylureas
seemed to provide less of a reduction in albuminuria independent
of glycaemic control compared with the DPP-4 inhibitor [46].
Another real-life study investigated the effects of two
commonly prescribed sulphonylureas on kidney outcomes in
4486 T2DM patients treated with either glimepiride or gliclazide
for > 2 years and followed for a median duration of 4.7 years
[47]. In a matched cohort using propensity scores with 12,122
person-years of follow-up, there was no signiﬁcant difference
between the two sulphonylureas in risk of ESRD or doubling of
creatinine, although there was a trend towards higher risks in the
glimepiride group than in the gliclazide group, reaching statistical
signiﬁcance in some subgroups [47].
Thus, sulphonylureas appear to exert less of a nephroprotective
effect, especially compared with metformin, although results from
observational studies require conﬁrmation by RCTs. In addition, no
study speciﬁcally investigated the effects of other insulin-secreting
agents, such as repaglinide and nateglinide, on UACR or any other
renal outcomes.
Alpha-glucosidase inhibitors
In animal models, the alpha-glucosidase inhibitor acarbose
suppressed blood glucose levels in mildly insulin-deﬁcient rats and
reduced the number of anionic sites in the glomerular basement
membrane, which might help to prevent its increased permeability
leading to albuminuria [48]. However, human data are scarce
[49]. In T2DM patients not well controlled by sulphonylureas and
metformin, additional acarbose therapy for 6 months provided
similar glycaemic control and changes in eGFR and UACR
compared with pioglitazone [50].
In the recent Acarbose Cardiovascular Evaluation (ACE) trial to
evaluate the effects of acarbose on CV and diabetes outcomes in
Chinese patients with coronary heart disease and impaired glucose
tolerance, after a median follow-up of 4.4 years, incidental
impaired renal function (deﬁned as eGFR < 30 mL/min/1.73 m2,
doubling of baseline serum creatinine or halving of baseline eGFR)
did not differ between the acarbose group and the placebo group
(41/3272 vs. 50/3250, respectively; HR: 0.81, 95% CI: 0.54–1.23;
P = 0.33) [51].
Glitazones
Of all the glucose-lowering agents, thiazolidinediones (TZDs)
are those with the greatest anti-inﬂammatory activity [52], an
effect that may contribute to nephroprotection [53]. TZDs may also
interfere with most of the pathogenetic pathways involved in the
development and progression of DKD, as they have been shown to
reduce hyperglycaemia and insulin resistance, lower arterial blood
pressure, improve endothelial function, reduce inﬂammatory
processes and oxidative stress, lower TGF-b and downregulate
the RAAS [54,55]. Data from several animal and human studies
support the notion that TZDs reduce UACR and may prevent the
development of renal impairment [55]. In a meta-analysis of
15 RCTs (ﬁve with rosiglitazone and 10 with pioglitazone)
involving 2860 T2DM patients, treatment with TZDs signiﬁcantly
decreased UACR and protein excretion [56]. However, in patients
with advanced diabetic nephropathy, no reduction in proteinuria
was observed in patients treated with pioglitazone compared with
glipizide for 4 months [57]. In a study that compared add-on
pioglitazone with basal insulin, both treatments improved
glycaemic control, but only pioglitazone was observed to
be advantageous by preserving renal function when used as ang agents on surrogate endpoints and hard clinical renal outcomes
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metformin regimens had failed [58].
In a small study of TD2M patients with microalbuminuria,
rosiglitazone compared with either nateglinide or placebo signiﬁ-
cantly reduced albumin excretion and ameliorated glomerular
hyperﬁltration at an early stage of T2DM as well as incipient DKD,
while also improving nitric oxide bioavailability and renal
endothelial dysfunction [59]. In ADOPT, initial monotherapy with
rosiglitazone slowed the rise of UACR compared with metformin,
preserved eGFR compared with glyburide, and lowered blood
pressure relative to both active comparators over a 5-year period
[34]. In a post-hoc analysis from the Prospective Pioglitazone
Clinical Trial in Macrovascular Events (PROactive), patients who had
DKD and were treated with pioglitazone compared with placebo
were less likely to reach the composite endpoint of all-cause death,
myocardial infarction and stroke, independently of the severity of
renal impairment. However, there was an unexpectedly greater
decline in eGFR with pioglitazone (between-group difference:
0.8 mL/min/1.73 m2/year) than with placebo [60]. Clinical renal
outcomes were not investigated in the study.
Therefore, whether the use of TZDs has a positive or negative
impact on renal outcomes in T2DM patients remains an open,
unanswered question [61]. In the recently published large-scale
prospective Insulin Resistance Intervention after Stroke (IRIS) trial,
which demonstrated signiﬁcant risk reductions of both recurrent
stroke and myocardial infarction with pioglitazone compared with
placebo as add-ons to standard care, no renal endpoints were
reported on [62]. Thus, the relative lack of evidence demonstrating
the effects of TZDs on hard renal outcomes mandates the need for
well-designed RCTs focused on this particular objective [55].
DPP-4 inhibitors
DPP-4is are incretin-based therapies that lower blood glucose
levels without inducing hypoglycaemia or weight gain while having
good CV safety proﬁles [63]. Their glucose-lowering efﬁcacy is
maintained in T2DM patients at all stages of CKD, and they are safe
to use [64–66]. However, it is recommended to reduce doses of
alogliptin, saxagliptin, sitagliptin and vildagliptin according to
reductions in eGFR to guarantee consistent drug exposures to these
medications, which are excreted via the kidneys [67,68]. In contrast,
as linagliptin has biliary rather than renal excretion, its usual dose
may be maintained whatever the state of renal function [69].
Several recent reviews have explored the effects of DPP-4is on
surrogate renal outcomes [70–72]. Renal protection has been
demonstrated in various animal models implicating different
underlying mechanisms independent of glucose control, including:
upregulation of GLP-1 and GLP-1 receptors; inhibition of renal
DPP-4 activity; attenuation of inﬂammasome activation, reduction
of oxidative stress; mitochondrial dysfunction and apoptosis;
suppression of connective-tissue growth factor; limitation of TGF-
b-related ﬁbrosis and nuclear factor (NF)-kB p65-mediated
macrophage inﬁltration; reduction of renal tubulointerstitial
ﬁbronectin; upregulation of stromal cell-derived factor-1; sup-
pression of advanced glycation end-products; regulation of
proliferation of preglomerular vascular smooth muscle and
mesangial cells; and attenuation of rises in blood pressure [70–
73]. However, despite such promising results in animal models,
data on surrogate biological markers of renal function (UACR,
eGFR) and clinical renal outcomes (progression to ESRD) are still
relatively scanty in patients with T2DM, and mostly demonstrate
the safety rather than true efﬁcacy of DPP-4is regarding renal
protection [70].
In overweight patients with T2DM without DKD, 12-week
treatment with sitagliptin had no measurable effect on renalPlease cite this article in press as: Scheen AJ. Effects of glucose-lowerin
in patients with type 2 diabetes. Diabetes Metab (2018), https://doihaemodynamics, and was not associated with sustained changes in
tubular function or alterations in markers of renal damage
[74]. The Trial to Evaluate Cardiovascular Outcomes after
Treatment with Sitagliptin (TECOS) was mainly a CV outcome
trial to demonstrate the CV safety of sitaglitptin [75]. In a post-hoc
analysis of TECOS, renal outcomes were evaluated over a median
period of 3 years, with participants categorized at baseline into
different eGFR stages [76]. Kidney function declined at the same
rate in both treatment groups, but with a marginally lower yet
constant eGFR difference (1.3 mL/min/1.73 m2) in those parti-
cipants assigned to sitagliptin compared with those receiving
placebo [76] (Table 2).
In the Saxagliptin Assessment of Vascular Outcomes Recorded
in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in
Myocardial Infarction (TIMI) 53 study [77], there were no
meaningful differences between the saxagliptin vs placebo
treatment arms, respectively, in any of the prespeciﬁed renal
safety outcomes: doubling of serum creatinine (2.02% vs. 1.82%);
initiation of chronic dialysis, renal transplantation, or serum
creatinine > 6.0 mg/dL (0.61% vs. 0.67%); and the composite of
doubling of serum creatinine, initiation of chronic dialysis, renal
transplantation and serum creatinine > 6.0 mg/dL (2.2% vs. 2.0%)
[78] (Table 2). Overall changes in eGFR during follow-up were
similar in the saxagliptin and placebo arms. However, a signiﬁcant
reduction in UACR was observed with saxagliptin compared with
placebo (34.3 mg/g; P < 0.004), driven mainly by decreased
levels in patients with macroalbuminuria at baseline (-283 mg/g;
P = 0.002), although changes in UACR did not correlate with those
in HbA1c [78]. The frequency of UACR progression was signiﬁcantly
lower with saxagliptin compared with placebo in all patients
except those with severe renal impairment. Other renal endpoints
appeared at relatively balanced rates in patients treated with
saxagliptin compared with placebo, irrespective of renal im-
pairment [79]. Also, in the Examination of Cardiovascular
Outcomes with Alogliptin versus Standard of Care (EXAMINE),
changes in eGFR from baseline (whatever the baseline level) and
rates of initiation of dialysis were similar between alogliptin and
placebo [80] (Table 2).
Finally, pooled analyses of placebo-controlled RCTs with
linagliptin revealed a 28% reduction in UACR (95% CI: 47 to 2;
P = 0.0357) [81] and 16% reduction in risk of composite DKD events
(HR: 0.84, 95% CI: 0.72–0.97; P = 0.02) compared with placebo
[82]. However, because of the limitations of such retrospective
analyses of rather short-term trials, the potential of linagliptin to
improve kidney disease outcomes still warrants further investiga-
tion. Indeed, in the Efﬁcacy, Safety and Modiﬁcation of Albuminuria
in Type 2 Diabetes Subjects with Renal Disease with Linagliptin
(MARLINA-T2D), a dedicated phase-III placebo-controlled RCT in
patients with inadequately controlled T2DM and evidence of DKD
(UACR with 30–3000 mg/g creatinine despite a stable background
of single RAAS blockade, and eGFR  30 mL/min/1.73 m2), lina-
gliptin signiﬁcantly improved glycaemic control with no signiﬁcant
effect on UACR compared with placebo and no signiﬁcant change in
placebo-adjusted eGFR [83]. Although there was no conclusive
evidence of renoprotective effects in the 24-week MARLINA-T2D
trial, previous research had suggested that clinically evident renal
beneﬁts might develop with longer-term treatment [84].
Overall, the renal-protective potential of DPP-4is remains
largely unproven in humans and merits further investigation
[70,72]. Several reasons may explain why DPP-4is failed to
positively impact renal outcomes in RCTs. First, they were designed
to demonstrate non-inferiority, rather than superiority, with CV
outcomes as primary endpoints. Furthermore, adjustment of
glucose-lowering therapies was allowed, which resulted in only
a small HbA1c difference between the active-treatment and
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in patients with type 2 diabetes. Diabetes Metab (2018), https://doilasting only 1.5 to 3 years. Thus, there is an urgent need for long-
term RCTs that are adequately powered and based on hard renal
outcomes to ascertain (or contradict) the therapeutic beneﬁts of
DPP-4is in patients with T2DM and DKD.
The placebo-controlled Cardiovascular and Renal Microvascular
Outcome Study with Linagliptin (CARMELINA) trial aimed to
evaluate the effects of linagliptin on both CV and kidney outcomes
in a study population of T2DM patients at high risk of CV and/or
kidney events [85]. The recruited population in this unique study
differed from those of previous studies with DPP-4is in that  60%
of patients had signs of renal dysfunction (either eGFR < 60 mL/
min/1.73 m2 or albuminuria), in contrast to < 25% in other trials.
While the primary outcome was the classic three-point combina-
tion of major CV events, the key secondary outcome was a
composite of time to ﬁrst sustained appearance of ESRD,  40%
decrease in eGFR from baseline and kidney-related death. The
results were presented at the 54th Annual Meeting of the European
Association for the Study of Diabetes (EASD; 4 October 2018), but
have yet to be published. No signiﬁcant differences were observed
between the linagliptin and placebo groups for either CV or renal
composite endpoints. Linagliptin was associated with a signiﬁcant
reduction in albuminuria with no effective change in eGFR.
GLP-1 receptor agonists
GLP-1RAs act on the traditional risk factors of progressive kidney
disease, including improvement of glucose control, lowering of
blood pressure and weight reduction. Moreover, GLP-1RAs may also
have direct effects on the kidney, including the intrarenal RAAS,
ischaemia/hypoxia, apoptosis and neural signalling (for a review,
see Thomas [17]). However, the mechanisms that may underlie any
direct actions in the kidney have yet to be established [86]. The GLP-
1 receptor seems to be expressed in glomeruli and arterioles,
whereas kidney-protective actions independent of the GLP-1
receptor have been proposed. GLP-1 induces natriuresis by reducing
sodium/hydrogen exchanger isoform 3 (NHE3)-dependent sodium
reabsorption in the proximal tubule [17,87]. GLP-1RAs have also
been shown to reduce inﬂammation, macrophage inﬁltration,
oxidative stress and type-IV collagen accumulation in the kidney
[17,88]. Because the beneﬁcial actions of liraglutide are known to be
inhibited by a speciﬁc adenylate cyclase inhibitor and a selective
protein kinase A (PKA) inhibitor, cAMP and PKA-dependent
pathways downstream of GLP-1 receptor activation may play a
critical role in renal protection [88]. In both in-vivo and in-vitro
studies, liraglutide prevented epithelial-to-mesenchymal transi-
tion, which plays a signiﬁcant role in the development of renal
ﬁbrosis, by inhibiting activation of the TGF-b1/Smad3 and ERK1/2
signalling pathways, and decreasing extracellular matrix secretion
and deposition [89]. Renal GLP-1 receptors have been found to be
present in afferent arteriolar vascular smooth muscle cells,
glomerular endothelial cells and macrophages, juxtaglomerular
cells and proximal tubule, while GLP-1 has been reported to
increase GFR, renal blood ﬂow, and fractional excretion of both
sodium and potassium [90].
GLP-1RAs are safe to use in T2DM patients with DKD [67]: 12-
week treatment with liraglutide had no measurable effects on renal
haemodynamics, and led to no observable sustained changes in
either tubular function or markers of renal damage [74]. In another
study, short-term liraglutide treatment also did not affect renal
haemodynamics, but did decrease proximal tubular sodium
reabsorption. Furthermore, a reduction in angiotensin II concentra-
tion was observed, which may contribute to renal protection [91].
In the Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) study of CV outcomes
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serum creatinine, ESRD and death from renal disease [93]. After a
median follow-up of 3.84 years in T2DM patients at high risk of CV
disease, this renal outcome was observed in fewer participants in
the liraglutide than in the placebo group (268/4668 patients vs.
337/4672, respectively; HR: 0.78, 95% CI: 0.67–0.92; P = 0.003;
Table III). However, this result was driven primarily by the new
onset of persistent macroalbuminuria, whereas no signiﬁcant
differences were observed for persistent doubling of serum
creatinine, ESRD and death due to renal disease (Table 3). The
decline in eGFR was slightly lower in the liraglutide than in the
placebo group (estimated 36-month trial ratio: 1.02, 95% CI: 1.00–
1.03; P = 0.01), corresponding to a 2% lower decrease with
liraglutide: 7.44 vs. 7.82 mL/min/1.73 m2). Rates of renal
adverse events (AEs) were similar in both liraglutide and placebo
groups (15.1 AEs and 16.5 AEs per 1000 patient-years, respective-
ly), including rates of acute kidney injury (7.1 AEs and 6.2 AEs per
1000 patient-years, respectively) [93].
In the Trial to Evaluate Cardiovascular and Other Long-term
Outcomes with Semaglutide in Subjects with Type 2 Diabetes
(SUSTAIN-6), after a median follow-up of 2 years, new or
worsening nephropathy was less frequently reported in T2DM
patients treated with semaglutide vs. placebo (HR: 0.64, 95% CI:
0.46–0.88; P < 0.01). Again, however, this composite outcome was
largely driven by a reduction in new-onset macroalbuminuria,
whereas doubling of serum creatinine concentrations resulting in
eGFRs  45 mL/min/1.73 m2, ESRD and death from renal causes
were unaffected [94] (Table III). In the Exenatide Study of
Cardiovascular Event Lowering (EXSCEL), a reduction in new-
onset macroalbuminuria was reported in patients treated with
once-weekly exenatide compared with placebo (2.2% vs 2.8%,
respectively; P = 0.03), with no signiﬁcant changes in either
microalbuminuria (7.2% vs. 7.5%, respectively) or ESRD requiring
renal replacement therapy (0.7% vs. 0.9%) after a median follow-up
of 3.2 years [95] (Table 3).
In T2DM patients who had had recent acute coronary events
from the Evaluation of Lixisenatide in Acute Coronary Syndrome
(ELIXA), 74.3% had normoalbuminuria, 19.2% had microalbumi-
nuria and 6.5% had macroalbuminuria [96]. After 108 weeks, the
placebo-adjusted, least-squares mean percentage changes in UACR
from baseline with lixisenatide were negligible in patients with
normoalbuminuria, but reached 21.10% (95% CI: 42.25–0.04;
P = 0.0502) in patients with microalbuminuria, and 39.18% (95%
CI: 68.53 to 9.84; P = 0.0070) in those with macroalbuminuria.
Lixisenatide was also associated with a reduced risk of new-onset
macroalbuminuria compared with placebo when adjusted for
baseline HbA1c (HR: 0.808, 95% CI: 0.660–0.991; P = 0.0404).
However, no signiﬁcant differences in eGFR decline were identiﬁed
between treatment groups in any UACR subgroup. In addition, the
proportion of patients with renal AEs was low and did not
signiﬁcantly differ between treatment groups [96].
Integrated data from nine phase-II/-III trials in T2DM patients
(n = 6005) showed that dulaglutide had no effect on eGFR, but did
decrease UACR slightly without increasing kidney AEs compared
with either placebo or active comparators [97]. In the 52-week
AWARD-7 trial of patients with T2DM and moderate-to-severe
DKD, once-weekly dulaglutide resulted in glycaemic control
similar to that achieved with insulin glargine with no greater
reduction in UACR, but with signiﬁcantly less of a decline in eGFR
(P = 0.005 for dulaglutide 1.5 mg and P = 0.009 for dulaglutide
0.75 mg vs. insulin) [98]. This was conﬁrmed by a US study in a
real-life setting where initiation of dulaglutide therapy, compared
with insulin glargine, was associated with a signiﬁcantly smaller
decrease in eGFR over a 1-year period [99]. Overall, these short-
term data suggest that dulaglutide has the potential to exert renal
protection in patients with T2DM, an effect that should bePlease cite this article in press as: Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes
in patients with type 2 diabetes. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.2018.10.003
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[100]. Further renal data will also become available when the
results of the ongoing CV outcome trial, Researching Cardiovascu-
lar Events with a Weekly Incretin in Diabetes (REWIND), are
published.
In the recently published Harmony Outcomes trial, albiglutide
was superior to placebo as regards major CV AEs in patients with
T2DM and CV disease (HR: 0.78, 95% CI: 0.68–0.90; P = 0.0006 for
superiority) [101]. A slight yet signiﬁcant difference in eGFR
between patients in the albiglutide group and those in the placebo
group was noted at 8 months (1.11 mL/min/1.73 m2, 95% CI:
1.84 to 0.39), but tended to disappear at 16 months (0.43 mL/
min/1.73 m2, 95% CI: 1.26–0.41). No increased risk of severe
renal AEs was reported wirh albiglutide. No other renal endpoint
data, including changes in albuminuria, are available from this
trial.
Divergent results have been reported in recent meta-analyses
investigating the effects of GLP-1RAs on microvascular complica-
tions. In the ﬁrst meta-analysis of 51 trials to report valuable
information on renal endpoints, GLP1-RAs lowered the incidence
of nephropathy [Mantel–Haenszel (MH) odds ratio (OR): 0.74, 95%
CI: 0.60–0.92; P = 0.005], and was signiﬁcantly different vs
placebo, but not vs any other class of active comparators
[102]. In another meta-analysis of 77 randomized trials involving
60,434 T2DM patients, treatment with GLP-1RAs was associated
with signiﬁcant reductions in all-cause and CV mortality, but with
no signiﬁcant decrease in risk of nephropathy (risk reduction:
0.866, 95% CI: 0.625–1.199; P = 0.385) [103]. In yet another meta-
analysis of 60 studies involving 60,077 T2DM patients, GLP-1RAs
marginally reduced UACR compared with placebo and other
antidiabetic agents [weighted mean difference (WMD): 2.55 mg/
g, 95% CI: 4.37 to 0.73, and 5.52 mg/g, 95% CI: 10.89 to
0.16, respectively], but resulted in no clinically relevant changes
in eGFR [104]. Of note, as the commercially available GLP-1RAs
may differ by a range of properties, whether or not there is a class
effect when considering cardiorenal protection remains an open
question [105,106].
SGLT2 inhibitors
SGLT2is exert their glucose-lowering effects by promoting
glucosuria, an effect that also results in body-weight and fat-mass
reductions. In addition to these effects, they increase natriuresis
and osmotic diuresis, thereby lowering arterial blood pressure and
plasma overload [107], all factors that may contribute to better CV
and renal outcomes and rates of mortality [108]. In addition,
switching from low-dose thiazide diuretics to SGLT2is has
improved various metabolic parameters (HbA1c, fasting plasma
glucose, serum uric acid, BMI, visceral fat area) without affecting
blood pressure in patients with T2DM and hypertension [109].
SGLT2is certainly represent the most promising pharmacologi-
cal class of glucose-lowering agents not only for CV factors, but also
for renal protection in T2DM patients [21,110]. In recent years,
numerous excellent and extensive reviews devoted to this topic
have summarized their preclinical and clinical data, and provided
several hypotheses to explain the nephroprotective effects of these
new antidiabetic agents [18,19,21,111–115]. SGLT2i effects on the
kidney are most likely explained by multiple pathways beyond
systemic effects via reductions in blood glucose, body-weight and
blood pressure. SGLT2is are associated with reduced glomerular
hyperﬁltration, an effect mediated through increased natriuresis,
and restored tubuloglomerular feedback independently of glycae-
mic control. Increased sodium and chloride delivery to the macula
densa following SGLT2 inhibition results in activation of renal
tubuloglomerular feedback, leading to afferent vasoconstrictionPlease cite this article in press as: Scheen AJ. Effects of glucose-lowerin
in patients with type 2 diabetes. Diabetes Metab (2018), https://doiand attenuation of diabetes-induced renal hyperﬁltration
[21,111]. This effect may explain the early decline in eGFR
commonly observed after initiation of SGLT2i therapy. This initial
drop is followed by a slower decline of eGFR thereafter compared
with placebo, an effect presumably explained by preservation of
glomerular integrity due to a reduction in intraglomerular pressure
[21,111]. In addition, SGLT2is may improve renal oxygenation and
cellular energy metabolism [21] while also reducing intrarenal
inﬂammation [116], thereby slowing the progression of kidney
function decline.
Recent results for biomarkers have suggested that the
albuminuria-lowering effect of SGLT2is may be the result of
decreased intraglomerular pressure or less tubular cell injury
possibly related to decreased inﬂammation [117] and perhaps also
linked to reduced activity of the intrarenal renin–angiotensin
system [118]. SGLT2is also lower serum uric acid levels [119,120],
an independent risk factor for diminished eGFRs in patients with
T2DM [121,122].
Because of their speciﬁc mechanism of action targeting the
kidney, SGLT2is lose part of their glucose-lowering activity when
eGFR falls to < 45–60 mL/min/1.73 m2, which means that their
use is no longer indicated and should be interrupted if levels are
below this threshold [123,124]. Nevertheless, the blood-pressure-
lowering effects of SGLT2is appear to be maintained [125,126], and
reductions in both major CV events and mortality have been
reported in subgroup analyses of T2DM patients with
eGFRs < 60 mL/min/1.73 m2 in CV outcome trials [127,128]. How-
ever, even though SGLT2is consistently reduce systolic blood
pressure [129], this speciﬁc effect apparently plays a minor role in
the improvement of either CV [130] or renal [131] outcomes.
In patients with T2DM at high CV risk recruited for the
Empagliﬂozin Cardiovascular Outcome Event Trial in Type
2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-
REG OUTCOME) [120], empagliﬂozin was associated with slower
progression of kidney disease, as reﬂected by reduced albuminuria
and a smaller decline in eGFR, and lower rates of clinically relevant
renal AEs, including progression to ESRD, compared with placebo
when added to standard care [132] (Table 4). Also, a detailed post-
hoc analysis supports both short-term and long-term beneﬁts of
empagliﬂozin on UACR, irrespective of albuminuria status at
baseline [133]. At week 12, the placebo-adjusted geometric mean
ratio of UACR changes from baseline with empagliﬂozin were 7%
(P = 0.013), 25% (P < 0.0001) and 32% (P < 0.0001) in patients
with normoalbuminuria, microalbuminuria and macroalbuminu-
ria, respectively, and these UACR reductions were maintained at
164 weeks. Indeed, patients treated with empagliﬂozin were more
likely to experience sustained improvements from microalbumi-
nuria to normoalbuminuria (HR: 1.43, 95% CI: 1.22–1.67;
P < 0.0001) and from macroalbuminuria to microalbuminuria or
normoalbuminuria (HR: 1.82, 1.40 to 2.37; P < 0.0001), and less
likely to experience sustained deterioration from normoalbumi-
nuria to microalbuminuria or macroalbuminuria (HR: 0.84, 0.74 to
0.95; P = 0.0077) [133]. Of note, reductions in major CV events and
mortality were also consistent across baseline categories of eGFR
and UACR [127]. In patients with prevalent DKD at baseline
(2250 of the whole cohort of 7020 patients), empagliﬂozin
compared with placebo reduced the risks of CV death by 29%
(HR: 0.71, 95% CI: 0.5–0.98), all-cause mortality by 24% (HR: 0.76,
95% CI: 0.59–0.99) and hospitalization for heart failure by 39% (HR:
0.61, 95% CI: 0.42–0.87). The effects of empagliﬂozin on these
outcomes were consistent across all baseline categories of eGFR
and UACR [127].
In the Canagliﬂozin Cardiovascular Assessment Study (CAN-
VAS) Program, prespeciﬁed outcomes included a composite of
sustained and adjudicated doubling of serum creatinine, ESRD and
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UACR [134,135]. The composite renal outcome presented less
frequently in the canagliﬂozin group compared with the placebo
group, with consistent ﬁndings across the prespeciﬁed patient
subgroups. Annual eGFR declines were slower and mean UACRs
were lower in participants treated with canagliﬂozin than with
placebo. After a rather short median follow-up of 2.4 years, only a
numerical trend for less progression to ESRD requiring renal
replacement therapy was noted [135] (Table IV). Renal outcomes
(HR: 0.59, 95% CI: 0.44–0.79 vs. HR: 0.63, 95% CI: 0.39–1.02; P =
0.73 for interaction) were similarly reduced in the secondary and
primary CV prevention cohorts, respectively [136]. In addition, the
relative effects on most of the CV and renal outcomes were similar
across all eGFR subgroups [128].
Canagliﬂozin compared with glimepiride slowed the progression
of renal disease over 2 years in patients with T2DM together with
reductions in albuminuria and declines in eGFR independently of its
glycaemic effects [137]. These renoprotective effects of canagliﬂozin
were conﬁrmed in a 1-year open-label study of Japanese T2DM
patients with CKD, which also showed a reduction in tubulointers-
titial markers [138]. The large-scale ongoing prospective Canagli-
ﬂozin and Renal Endpoints in Diabetes with Established
Nephropathy Clinical Evaluation (CREDENCE) compares the efﬁcacy
and safety of canagliﬂozin vs. placebo in preventing clinically
important kidney and CV outcomes (primary outcome is a composite
of ESRD, doubling of serum creatinine and renal or CV death) in
patients with T2DM and established CKD [139]. A similar study is
also ongoing with dapagliﬂozin [A Study to Evaluate the Effect of
Dapagliﬂozin on Renal Outcomes and Cardiovascular Mortality in
Patients with Chronic Kidney Disease (Dapa-CKD); ClinicalTrials.gov
identiﬁer: NCT03036150] to conﬁrm and extend the preliminary
positive results for albuminuria over 2 years with dapagliﬂozin
therapy in T2DM patients with renal impairment [140].
Nevertheless, even though SGLT2is have elicited considerable
enthusiasm, they may be associated with AEs, some of which are
potentially severe, thereby requiring that individual beneﬁt–risk
ratios be taken into consideration [141,142]. Indeed, despite the
encouraging renal outcomes described above, scattered reports
have suggested the possible risk of acute kidney injury that may,
on occasions, require renal replacement therapy [143]. Therefore,
several mechanisms have been proposed to explain this risk with
SGLT2is, including: effective volume depletion (with dehydration
or diuretic therapy); excessive decline in transglomerular pressure
(with concomitant RAAS blockade); and induction of renal
medullary hypoxic injury (triggered by, for example, non-steroidal
anti-inﬂammatory drugs) [123,142]. Given the higher proportion
of reports of acute renal failure with SGLT2is in the US Food and
Drug Administration Adverse Event Reporting System (FAERS)
database [144], the FDA now requires that acute kidney injury be
listed as a potential side-effect of SGLT2is while cautioning careful
prescription of these drugs with the other above-mentioned
medications.
In the event, it is imperative to ascertain whether the reported
acute renal failure represents true structural kidney injury or a
functional decline in eGFR [145]. The available data support the
latter, especially in circumstances exposing patients to dehydra-
tion. In the EMPA-REG OUTCOME, the number of patients (mostly
being treated with RAAS blockers) who developed acute renal
failure appeared to be less in the group treated with the SGLT2i
than with placebo [132]. In fact, when SGLT2is are properly used in
clinical practice, acute kidney injury is a rare event. In addition, a
network and cumulative meta-analysis of RCTs has provided
diverse results for three SGLT2is regarding risk of renal AEs,
thereby indicating that more data from large long-term RCTs and
well-conducted observational studies in real-life settings are
clearly warranted before any conclusions can be drawn [146].g agents on surrogate endpoints and hard clinical renal outcomes
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Surprisingly, few data have been published to support the
nephroprotective effects of insulin in experimental preclinical
studies, which contrasts with the unexpected interest devoted to
C-peptide almost a decade ago [147,148]. Yet, several key elements
of the insulin-signalling cascade contribute to podocyte function
and survival [149], and the insulin receptor is crucial for renal
function in the glomeruli and tubules. When signalling is
diminished in, for example, insulin-resistant states, it may be
responsible for a number of important renal complications,
including glomerular disease and albuminuria, leading to hyper-
tension [150]. Also intriguing is the fact that the effects of insulin
therapy on renal outcomes have been poorly investigated in
patients with T2DM, and that the data from available RCTs are
scarce and difﬁcult to interpret for several reasons. In the UKPDS,
newly diagnosed T2DM patients were at low renal risk, and the
intensive group included sulphonylurea-treated and insulin-
treated patients [151,152]. In the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study, Veterans Affairs Diabetes Trial
(VADT) and ADVANCE, intensiﬁcation of blood glucose control was
based on more insulin therapy, but not exclusively, making it
difﬁcult to differentiate the effects of reduction of hyperglycaemia
from those of insulin per se [153]. Finally, the Outcome Reduction
with Initial Glargine Intervention (ORIGIN) trial included patients
with dysglycaemia, and renal outcomes were not analyzed
separately from eye disease [154].
Few studies have provided data on renal endpoints when
comparing insulin therapy with other glucose-lowering medica-
tions, and none have supported better nephroprotection by insulin.
In a retrospective cohort study using data from the UK General
Practice Research Database, exogenous insulin therapy compared
with metformin monotherapy as the reference was associated with
an increased risk of diabetes-related complications, including renal
complications. However, differences in baseline characteristics
between treatment groups (more advanced and complicated
disease in insulin-treated patients) should be considered when
interpreting these results [155]. Of the patients who intensiﬁed their
metformin monotherapy in the US Veterans Affairs national
database, the addition of insulin compared with a sulphonylurea
was not associated with a lower rate of adverse kidney outcomes
(persistent eGFR decline  35% from baseline, a diagnosis of ESRD).
In contrast, it was associated with a higher rate of the composite
outcome, including death, which was not modiﬁed according to
baseline eGFR [156]. In the previously mentioned AWARD-7 trial,
although insulin glargine was associated with a slightly greater
decline in eGFR compared with once-weekly dulaglutide at
52 weeks, both treatments provided similar glycaemic control in
patients with T2DM and moderate-to-severe DKD [98]. In a US study
within a real-life setting, initiation of insulin glargine compared
with dulaglutide therapy was associated with a signiﬁcantly greater
decrease in eGFR after 1 year together with a smaller reduction in
HbA1c [99]. Finally, in a study comparing basal insulin with
pioglitazone as an add-on therapy for T2DM patients for whom
sulphonylurea and metformin regimens had failed, both treatments
improved glycaemic control, whereas only pioglitazone proved
advantageous in terms of preserving renal function [58].
Combined therapies
DKD in T2DM is a complex disorder that requires multifactorial
interventions to minimize the risk, and RAAS inhibitor therapy is
the mainstay of DKD prevention [6]. In T2DM patients at high CV
risk recruited for four large prospective trials showing signiﬁcant
reductions in renal outcomes (LEADER, SUSTAIN-6, EMPA-REGPlease cite this article in press as: Scheen AJ. Effects of glucose-lowerin
in patients with type 2 diabetes. Diabetes Metab (2018), https://doiOUTCOME, CANVAS), almost three-quarters of all patients were
treated with RAAS blockers. The potential complementary
mechanism between RAAS inhibitors and SGLT2is has been
emphasized, as discussed in a recent review [157].
When focusing on glucose-lowering therapies, a large majority
of patients included in the above-mentioned trials were treated
with metformin at baseline and throughout the follow-up period.
Thus, liraglutide, semaglutide, empagliﬂozin or canagliﬂozin were
added to the standard care which, in most patients, comprised
metformin; the latter, however, was prescribed at similar
percentages in both the tested drug and placebo groups.
A promising combination is the association of an SGLT2i with a
GLP-1RA: they appear to be synergistic and, at least according to
the available short-term data for each pharmacological approach,
this combination may yet be the most useful way to protect the
kidney (and heart as well) in T2DM patients [158]. However, the
strategy still requires further validation in clinical trials with a
focus on CV and renal outcomes before it can be recommended for
more extensive use in clinical practice, especially as such a drug
combination is more expensive. Moreover, whether the addition of
pioglitazone might also result in better renal outcomes, as has been
postulated for CV outcomes [159], remains an open question.
Conclusion
The overall number of patients with DKD is high and is expected
to continue to increase in parallel with the growing global T2DM
pandemic. Yet, based on some landmark clinical trials, DKD is
preventable by controlling conventional factors, including hyper-
glycaemia and hypertension, using a combination of lifestyle
approaches and multifactorial drug therapies. Of the pharmaco-
logical approaches, RAAS inhibitors are considered the cornerstone
of renal protection, especially in T2DM patients with (micro)-
albuminuria. Nevertheless, the remaining risk of DKD progression
is still high.
Improving glucose control remains essential to either prevent
or slow the progression of DKD. Yet, despite the numerous positive
results in preclinical studies, most glucose-lowering agents have
only shown favourable effects on surrogate endpoints, such as
albuminuria, in clinical studies, with almost no evidence of
positive effects on hard renal outcomes (Table 1). In contrast, GLP-
1RAs and SGLT2is have proven their ability to reduce composite
renal outcomes including albuminuria, eGFR decline, doubling of
creatinine and progression to ESRD or kidney-related death.
However, only SGLT2is have proved capable of reducing hard
clinical endpoints, such as doubling of creatinine and progression
to ESRD, while the positive effects of GLP-1RAs on composite renal
outcomes were mainly driven by the reduction of new-onset
macroalbuminuria. This is why the updated 2018 consensus report
by the American Diabetes Association (ADA) and European
Association for the Study of Diabetes (EASD) has recommended
that, for patients with T2DM and CKD with or without CV disease,
the ﬁrst therapeutic option considered should be an SGLT2i shown
to reduce DKD progression or, if contraindicated (eGFR is less than
adequate) or not preferred, a GLP-1RA to exert CV protection
[160]. Of note, as these nephroprotective effects are independent of
glucose-lowering, the underlying mechanisms remain a subject of
debate. Besides their positive effects on systemic factors such as
blood glucose, body weight and blood pressure, GLP-1RAs and
SGLT2is exert their nephroprotection mainly via direct intrarenal
effects related to haemodynamic changes or their anti-inﬂamma-
tory/antioxidative/antiﬁbrotic activities.
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